ADCs, or antibody drug conjugates, are a type of highly specific biopharmaceutical drug that use chemical linkers to join together monoclonal antibodies that target surface antigens on specific tumor cells with extremely effective anticancer agents.
Antibody-drug conjugates are a simple way to get “deactivated” cytotoxins to cancer cells. When a cytotoxin is taken up by a tumor cell (a process known as internalization), it regains its full cytotoxic activity and can once again kill cancer cells. This leads to rapid cell death.
While thousands of different cellular toxins can be derived from nature or synthesized in a lab, only a select few can be used as parts of an antibody-drug conjugate (ADCs). Early ADCs were made from already-approved chemotherapeutic drugs like doxorubicin and methotrexate.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/181
Global Antibody Drug Conjugates Market – Impact of the Coronavirus (COVID-19) Pandemic
On January 31, 2019, a coronavirus (COVID-19) outbreak was first reported in Wuhan, China. On March 11, 2020, COVID-19 was officially declared a pandemic by the World Health Organization. Over 225 million cases and 4.63 million deaths were reported worldwide due to coronavirus (COVID-19), as reported by the World Health Organization’s Coronavirus (COVID-19) Weekly Epidemiological Update as of September 14, 2021.
Effect of COVID-19 on Demand and Supply of Antibody Drug Conjugates
The global spread of the COVID-19 pandemic and subsequent lockdowns in many countries have had a negative effect on the bottom lines of companies in all industries, including the private healthcare sector. Due in large part to lockdown in several regions, the COVID-19 pandemic has affected the entire healthcare supply chain. There are three primary ways in which the COVID-19 pandemic has impacted economies around the world: (1) through direct effects on production and demand, (2) through disruptions in distribution channels, and (3) through monetary effects on businesses and financial markets. There are issues with the distribution and transport of medical supplies in several countries, including Thailand, Indonesia, and Singapore.
As a result, the global market for antibody drug conjugates is predicted to grow at a slower rate than it otherwise would due to the effect of the coronavirus (COVID-19) pandemic on the cancellation of cancer screenings and delayed hospital visits on the progression and prognosis of the disease. The article in The Lancet Oncology from July 2021 reports the results of an ambidirectional cohort study conducted at 41 cancer centers in India that are part of the National Cancer Grid of India to make comparisons oncology service provision between March 1, 2020 and May 31, 2020, with the same period in 2019. Cancer treatment was found to be significantly affected by the COVID-19 pandemic, as shown by the results of a cohort study. Screening, treatment, diagnosis, palliative care, and follow-up were all scaled back during the pandemic. These cuts will almost certainly cause at least some patients who were likely to be diagnosed with cancer during such a time to receive a later diagnosis and less effective treatment.
By the end of the forecast period in 2021, the worldwide market for antibody drug conjugates is anticipated to have reached a value of $4.29 billion (2021-2028).
The rising prevalence of breast cancer, which is currently treated with antibody drug conjugates, is anticipated to be a major growth driver for the market in the coming years.
Rising rates of breast cancer are anticipated to fuel demand for antibody drug conjugates worldwide. For example, in 2018, the United States reported 254,744 new cases of breast cancer in women, with 42,465 women succumbing to the disease. In addition, there were 127 new cases of breast cancer and 20 deaths from cancer in 2018 for every 100,000 women.
Research and Development Activities
The global market for antibody drug conjugates is forecast to expand lucratively thanks to rising investment in R&D. For example, at the 62nd annual meeting of the American Society of Hematology (ASH) in 2020, on December 07, 2020, ADC Therapeutics SA, a late-stage biotechnology company concentrated on oncology, declared the latest clinical evidence of its two leading projects, Loncastuximab-Tesirine (Lonca) and Camidanlumab-Tesirine (Cami). Using a linker, the humanised monoclonal antibody Loncastuximab Tesirine targets human Cluster of Differentiation (CD) 19 and is then conjugated to the pyrrolobenzodiazepine (PBD) dimeric cytotoxin. The monoclonal antibody Camidanlumab Tesirin binds to CD25, and it is conjugated to the pyrrolobenzodiazepine (PBD) dimer payload tesirin to create an antibody drug conjugate (ADC).
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/181
Global Antibody Drug Conjugates Market – Regional Analysis)
The global market for antibody drug conjugates is divided into the North American market, the Latin American market, the European market, the Asian market, the Middle Eastern market, and the African market.
During the forecast period, the antibody drug conjugates market in North America is anticipated to lead the world. This is mainly because of the increasing number of products being developed and approved for use in the region. The FDA granted ZYNLONTA (Loncastuximab Tesirinelpyl) for the diagnosis of relapsed or refractory large B-cell lymphoma on April 23, 2021, according to a press release from ADC Therapeutics SA, a next-generation biotechnology company specializing in oncology. ZYNLONTA, an antibody-drug conjugate that targets CD19, was granted fast-track approval by the U.S. Food and Drug Administration due to the impressiveness of its overall response rate.
The Asia-Pacific region is anticipated to be the fastest-growing region in the global antibody drug conjugates market over the forecast period. This is largely attributable to the growing number of strategic partnerships among market players. For example, on November 27, 2018, Zymeworks Inc., a biopharmaceutical company in the development phase, and BeiGene, Ltd., a biopharmaceutical company in the commercialization phase, announced a strategic partnership for the development and commercialization of the bi-specific antibodies ZW25 and ZW49 HER2. Bispecific antibody drug conjugate (ADC) ZW49 is in preclinical development by Zymeworks, and BeiGene has been granted exclusive rights to develop and commercialize ZW49 in Asia (excluding Japan), New Zealand and Australia.
Global Antibody Drug Conjugates Market – Competitive Landscape
The main companies participating in the market of antibody drug conjugates worldwide are F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Ltd., Astellas Pharma, ADC Therapeutics, Pfizer, Inc., Seagen, Inc., Daiichi Sankyo Company Ltd., and Oxford Biotherapeutics.
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/181
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Antibody Drug Conjugates Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Antibody Drug Conjugates Industry Impact
Chapter 2 Global Antibody Drug Conjugates Competition by Types, Applications, and Top Regions and Countries
2.1 Global Antibody Drug Conjugates (Volume and Value) by Type
2.3 Global Antibody Drug Conjugates (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Antibody Drug Conjugates Sales, Consumption, Export, Import by Regions (2017-2023)
Chapter 5 North America Antibody Drug Conjugates Market Analysis
Chapter 6 East Asia Antibody Drug Conjugates Market Analysis
Chapter 7 Europe Antibody Drug Conjugates Market Analysis
Chapter 8 South Asia Antibody Drug Conjugates Market Analysis
Chapter 9 Southeast Asia Antibody Drug Conjugates Market Analysis
Chapter 10 Middle East Antibody Drug Conjugates Market Analysis
Chapter 11 Africa Antibody Drug Conjugates Market Analysis
Chapter 12 Oceania Antibody Drug Conjugates Market Analysis
Chapter 13 South America Antibody Drug Conjugates Market Analysis
Chapter 14 Company Profiles and Key Figures in Antibody Drug Conjugates Business
Chapter 15 Global Antibody Drug Conjugates Market Forecast (2023-2030)
Chapter 16 Conclusions
Explore Our More Related Insights:
India immune oncology drugs market
Ornithine transcarbamylase otc deficiency treatment market
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027